Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results - Wikidata - awgldk - TriplyDB

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

http://www.wikidata.org/entity/Q28262507

about

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor Axitinib for the management of metastatic renal cell carcinoma Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions Axitinib in Metastatic Renal Cell Carcinoma Epithelial tumours of the lacrimal gland: a clinical, histopathological, surgical and oncological survey Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Novel approaches in anaplastic thyroid cancer therapy Development of second-generation VEGFR tyrosine kinase inhibitors: current status.Multikinase inhibitors use in differentiated thyroid carcinoma.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma.Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer.Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma Thyroid cancer: emerging role for targeted therapies.Targeted treatment of differentiated and medullary thyroid cancer.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Targeting the tumor microenvironment: focus on angiogenesis.Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics Topical axitinib suppresses angiogenesis pathways induced by pulsed dye laser.New therapies for dedifferentiated papillary thyroid cancer Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.

P2860

Q24594930-3204A23D-027D-48E3-B21F-8EB2B3FBC710 Q24613720-4C8489E8-F9C1-4664-88FA-1C4D82F57A89 Q26751341-44A16B52-A054-4E21-91CA-71DB18813AD3 Q26863326-2FC3EE80-3740-401E-8222-46B783B94339 Q26998017-19A237DA-CB9B-4418-9BCD-3442B6F2EF28 Q27025842-41C3CB5B-9213-48FC-A5DC-F9BE916C643C Q27028048-F6913F21-B074-403C-803E-187516383B18 Q28072655-8569CABB-7562-4889-A197-CB57E29524DA Q30301145-0D4A3143-72D5-4EA5-82B8-994BEA9482ED Q30317831-98CD53A6-7549-431C-B32D-BBD1BA726F1B Q33408127-B6AFC4FC-51E5-485A-866E-345F20D91D81 Q33429478-D4BF6668-A8F3-4A04-8B2F-D26486317EFB Q33433070-452923DB-84CA-43AA-92D6-9160B06A17C0 Q33554432-EBF8446B-2DAB-4ADA-ABF2-5DC73B406589 Q33622982-B6D05DBE-2064-40A1-9786-8FC5FBE25271 Q33633424-1962131E-3006-41D6-BCE7-863EC6837693 Q33918044-DD40B563-B01D-466A-98FD-85A75F2524B3 Q33973831-AEF5907F-96FB-41F6-8B10-C22A041447C4 Q33997879-554D9C53-6A9D-4BC2-A317-557F49357131 Q34245458-BECC12A9-09AA-496A-9B19-7984F8BB65A0 Q34458018-DCD7EA55-08C5-482C-BB80-ED8FDA7E858D Q34616440-3A604807-8A4B-4848-A0FC-1D6B97E822C8 Q34660901-97C31386-314B-4397-B213-BD1E8DC620DD Q34661185-A7532E0B-129B-4115-A42C-B198B78E7DAB Q34693856-BF9FA380-ABCF-4D7A-9103-75B343170FB9 Q34854658-AE5A142D-C753-41C5-AC45-0441116EEB44 Q34923902-BC18E142-8BD6-49F8-A1CA-997095F20569 Q35000792-983223E4-90A3-4615-AAEA-0C6606C5F4FD Q35050210-940BA855-5339-4211-82DB-CCE0D54998E4 Q35052037-678309D9-9C23-4BBD-B97B-DD85ABB8E193 Q35076227-4344EF1C-52FE-4F0E-A5A0-5DD23AB3B40A Q35147151-1B6E5B58-6D31-4CCD-AABB-9EF0A85CD9BE Q35171274-42315B7E-6C27-4FF5-93BD-BC62278727C4 Q35184806-392B3F9D-ADE3-4C65-A5F8-DDF0D064CBBF Q35209594-658D2087-5090-4E62-A342-AFD781FFC292 Q35302906-60461B79-65EE-4388-84AF-D80280FDD43D Q35381593-D59D0545-8011-4700-9C2A-7618BDE137FA Q35584072-FDB17310-3F0E-404E-A665-81A707BCD621 Q35584543-DF3051F2-6012-4606-B994-C4910F5BFC75 Q35626845-49EF3C0F-E4FE-4590-8C41-51B75D19DCCA

P2860

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

http://www.wikidata.org/entity/Q28262507

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Phase I trial of the oral anti ...... cokinetic and clinical results

@ast

Phase I trial of the oral anti ...... cokinetic and clinical results

@en

Phase I trial of the oral anti ...... cokinetic and clinical results

@nl

type

label

Phase I trial of the oral anti ...... cokinetic and clinical results

@ast

Phase I trial of the oral anti ...... cokinetic and clinical results

@en

Phase I trial of the oral anti ...... cokinetic and clinical results

@nl

prefLabel

Phase I trial of the oral anti ...... cokinetic and clinical results

@ast

Phase I trial of the oral anti ...... cokinetic and clinical results

@en

Phase I trial of the oral anti ...... cokinetic and clinical results

@nl

P1433

Q28262507-C98B3CAE-59FC-47AD-8CEE-3CC6BA8EAC9B

P1476

Q28262507-B2E0C56E-0C4F-4519-BBC8-A20144B1C99B

P2093

Q28262507-10DB23EC-D01D-4EE2-8D9A-29E28369D99F

Q28262507-10E203F5-9A75-460D-8ADE-726E920A6E78

Q28262507-32E6321D-98A3-4F73-BCCB-BE3867B27671

Q28262507-4DEEC4E2-061B-4B8F-A9A7-36FEB3A0E384

Q28262507-8E68B88E-AFE3-4FF2-8BAE-EC8711E15826

Q28262507-B037A853-9706-4D87-A504-BF2187060B4F

Q28262507-CE880EB0-FA28-440C-A3E1-D544BC62990F

Q28262507-D42A1F29-7B83-4DC7-906F-0556B0D2A37B

P304

Q28262507-6457F5AE-FF95-49D5-8FC9-2B55CAB645FD

P31

Q28262507-6E054E65-C770-446F-8F5C-1129900E794F

P3181

Q28262507-07CBB099-AAFA-45CF-BE1D-DA54A924B384

P356

Q28262507-F8B4212E-FCC8-485B-9DB8-9C0B14C314E7

P407

Q28262507-97FBE113-936F-4222-8072-05A56A3D4F38

P433

Q28262507-BAD81B3D-A144-4B2A-AE81-1E83E1CD9392

P478

Q28262507-C3B6652F-3D79-4318-A33C-ECAE20101D97

P50

Q28262507-0C05B0E2-2EEE-4333-837C-07C4B799298F

Q28262507-27727302-6345-463F-B409-D92B712178B6

P577

Q28262507-775D325C-0B98-4889-B9DF-30480A76CF08

P698

Q28262507-3FED6470-12C2-41F8-B0D4-FE276CC96238

P921

Q28262507-009CAEC2-BF51-4B93-B16B-94EFB7BDEAD9

Q28262507-14465C85-16DE-4AFA-BF13-591914CB9922

Q28262507-F20C18E8-1CF1-4209-928A-9164D0493C96

P3181

P356

JCO.2005.04.192

P1433

Journal of Clinical Oncology

P1476

Phase I trial of the oral anti ...... cokinetic and clinical results

@en

P2093

Glenn Liu

http://www.w3.org/2001/XMLSchema#string

Heidi M Steinfeldt

http://www.w3.org/2001/XMLSchema#string

Hope S Rugo

http://www.w3.org/2001/XMLSchema#string

James L Freddo

http://www.w3.org/2001/XMLSchema#string

John W Park

http://www.w3.org/2001/XMLSchema#string

Merrill S Kies

http://www.w3.org/2001/XMLSchema#string

Steven D Reich

http://www.w3.org/2001/XMLSchema#string

Yazdi K Pithavala

http://www.w3.org/2001/XMLSchema#string

P304

5474-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1185092

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2005.04.192

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16027439

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

phase I clinical trial